AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China
Completed
- Conditions
- Hyperkalaemia
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT05271266
- Locations
- 🇨🇳
Research Site, Xinghua, China
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Completed
- Conditions
- Severe Eosinophilic Asthma
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3
- Registration Number
- NCT05271526
- Locations
- 🇷🇺
City clinical hospital No57, Moscow, Russian Federation
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Phase 1
Completed
- Conditions
- Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT05266404
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05267613
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Phase 3
Recruiting
- Conditions
- CarcinomaNon-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 324
- Registration Number
- NCT05261399
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
Phase 3
Completed
- Conditions
- Eosinophilic GastroenteritisEosinophilic Gastritis
- Interventions
- Biological: PlaceboBiological: Benralizumab
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT05251909
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines
Completed
- Conditions
- Covid-19
- Interventions
- Other: Pre-COVID-19Other: COVID-19Other: COVID-19 vaccination roll-out
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7641136
- Registration Number
- NCT05252442
- Locations
- 🇬🇧
Research site, Oxford, United Kingdom
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 666
- Registration Number
- NCT05251259
- Locations
- 🇬🇧
Research Site, Watford, United Kingdom
Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT05250011
- Locations
- 🇮🇹
Research Site, Napoli, Italy
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
Phase 2
Completed
- Conditions
- HER2-mutant Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT05246514
- Locations
- 🇨🇳
Research Site, Zhengzhou City, China
© Copyright 2025. All Rights Reserved by MedPath